Completed PHASE3 INTERVENTIONAL 4-arm NCT00545740

Prevention of Recurrence of Diverticulitis (PREVENT1)

A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.

Sponsor: Shire

Conditions Diverticulitis

Interventions Placebo SPD476 (1.2g) SPD476 (2.4 g) SPD476 (4.8 g)

Updated 2 times since 2024 Last updated: Jun 8, 2021 Started: Nov 28, 2007 Primary completion: Mar 5, 2012 Completion: Mar 5, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diverticulitis, this trial is completed. The trial is conducted by Shire and has accumulated 2 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Afula, Israel , Ahmedabad, India , Anaheim, United States , Anderson, United States , Ashkelon, Israel , Auckland, New Zealand , Ballarat, Australia , Baltimore, United States , Barcelona, Spain and 96 more locations